Vaishali Pharma (VAISHALI) Q2 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 25/26 earnings summary
26 Nov, 2025Executive summary
Un-audited financial results for the quarter and half year ended September 30, 2025, were approved by the Board and reviewed by statutory auditors, with no material misstatements identified.
Financial highlights
Standalone revenue from operations for H1 FY26 was ₹5,719.34 lakhs, up from ₹3,886.55 lakhs in H1 FY25.
Standalone net profit for H1 FY26 was ₹246.38 lakhs, compared to ₹81.74 lakhs in H1 FY25.
Consolidated net profit for H1 FY26 was ₹246.57 lakhs, including ₹0.19 lakhs share of profit from associate.
Earnings per share (basic and diluted) for H1 FY26 stood at ₹0.19, up from ₹0.06 in H1 FY25.
Outlook and guidance
The company continues to focus on its core segment of pharmaceutical product sales.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Vaishali Pharma
- Q1 FY27 net profit rose to ₹148.97 lakh standalone, with consolidation of Kesar Pharma boosting group results.VAISHALI
Q1 26/27 - Strong revenue and profit growth, with new associate consolidation and auditor caution on receivables.VAISHALIQ4 25/26
- Q3 FY26 profit rose sequentially, preferential issue to raise ₹12.25 crore approved.VAISHALIQ3 25/26
- Q1 FY26 saw higher revenue but lower net profit and EPS amid rising expenses.VAISHALIQ1 25/26
- Revenue and profit rose, but auditor flagged major uncertainty over receivables' recovery.VAISHALIQ4 24/25
- Revenue and net profit rose year-over-year, with strong equity growth and robust financing inflows.VAISHALIQ2 24/25
- Q1 FY25 saw higher revenue, a return to profit, and increased share capital.VAISHALIQ1 24/25
- Q3 FY25 revenue was flat, but net profit fell on higher costs; auditors found no misstatements.VAISHALIQ3 24/25